AJP - Endo Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 240: E325-E332, 1981;
0193-1849/81 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (34)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caro, J. F.
Right arrow Articles by Amatruda, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caro, J. F.
Right arrow Articles by Amatruda, J. M.

AJP - Endocrinology and Metabolism, Vol 240, Issue 3 325-E332, Copyright © 1981 by American Physiological Society


ARTICLES

Evidence for modulation of insulin action and degradation independently of insulin binding

J. F. Caro and J. M. Amatruda

The interrelationships between insulin binding, action, and degradation were investigated in isolated hepatocytes with the aid of an insulin-receptor antibody (IRA) preparation that does not affect insulin binding. These IRA have insulin-like effects as determined by their ability to stimulate [14C]acetate incorporation into lipids. However, this effect is less than that of insulin; and in the presence of insulin and IRA, the effects of insulin are partially inhibited. The IRA have no effect on lipogenesis stimulated by postreceptor insulin "mimickers." The IRA also significantly inhibit insulin degradation. However, they do not affect insulin degradation in the presence of a large excess of unlabeled hormone. Taken together these data demonstrate that insulin action and degradation can be modulated independently of binding and suggest that the IRA partially inhibit insulin action and degradation through a portion of the insulin receptor that is not a determinant of insulin binding. It is possible, however, that there exist in the antiserum heterogeneous antibodies that bind to nonreceptor sites on the plasma membrane and mediate some of the phenomena observed.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online